Clinical trial
Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage…
NCT00262782 · German CLL Study Group, Other · Completed
Key facts
| NCT number | NCT00262782 |
|---|---|
| Title | Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia |
| Official title | Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia |
| Lead sponsor | German CLL Study Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Fludarabine |
| Enrollment | 877 |
| Start date | Apr 1, 1997 |
| Primary completion | Dec 1, 2004 |
| Completion | Jun 1, 2010 |
| First posted | Dec 7, 2005 |
| Last update posted | Feb 20, 2020 |
| Countries | Austria, Germany |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: